首页> 外文期刊>Stem Cell Reports >Differentiation-Defective Human Induced Pluripotent Stem Cells Reveal?Strengths and Limitations of the Teratoma Assay and In?Vitro Pluripotency Assays
【24h】

Differentiation-Defective Human Induced Pluripotent Stem Cells Reveal?Strengths and Limitations of the Teratoma Assay and In?Vitro Pluripotency Assays

机译:分化缺陷的人类诱导多能干细胞揭示了畸胎瘤测定和体外多能测定的强度和局限性

获取原文
           

摘要

Summary The ability to form teratomas in?vivo containing multiple somatic cell types is regarded as functional evidence of pluripotency for human pluripotent stem cells (hPSCs). Since the Teratoma assay is animal dependent, laborious, and only qualitative, the PluriTest and the hPSC ScoreCard assay have been developed as in?vitro alternatives. Here we compared normal hPSCs, induced hPSCs (hiPSCs) with reactivated reprogramming transgenes, and human embryonal carcinoma cells (hECs) in these assays. While normal hPSCs gave rise to typical teratomas, the xenografts of the hECs and the hiPSCs with reactivated reprogramming transgenes were largely undifferentiated and malignant. The hPSC ScoreCard assay confirmed the line-specific differentiation propensities in?vitro. However, when undifferentiated cells were analyzed by the PluriTest, only hECs were identified as abnormal whereas all other cell lines were indistinguishable and resembled normal hPSCs. Our results indicate that pluripotency assays are best selected on the basis of intended downstream applications.
机译:总结包含多种体细胞类型的体内形成畸胎瘤的能力被认为是人类多能干细胞(hPSC)多能性的功能证据。由于Teratoma检测是动物依赖性的,费力的并且仅是定性的,因此已经开发了PluriTest和hPSC ScoreCard检测作为体外替代品。在这里,我们比较了正常的hPSC,诱导的hPSC(hiPSC)与重新激活的重编程转基因以及人类胚胎癌细胞(hEC)。尽管正常的hPSC产生典型的畸胎瘤,但具有重新激活的重编程转基因的hEC和hiPSC的异种移植在很大程度上未分化和恶变。 hPSC ScoreCard分析证实了体外特定株系的分化倾向。但是,当通过PluriTest分析未分化的细胞时,只有hEC被鉴定为异常,而所有其他细胞系却无法区分并且类似于正常的hPSC。我们的结果表明,在预期的下游应用的基础上,最好选择多能性测定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号